Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference (RNAi) ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, ...